Please try another search
For the three months ended 31 March 2016, Epirus Biopharmaceuticals Inc revenues increased from $25K to $803K. Net loss increased from $7.5M to $16.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase from $3M to $10.1M (expense), General and administrative increase of 55% to $6.5M (expense).
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 0.8 | 0.41 | 0.22 | 0.04 |
Gross Profit | 0.28 | |||
Operating Income | -16.01 | -15.01 | -14.04 | -15.01 |
Net Income | -16.27 | -15.39 | -13.99 | -15.29 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 61.34 | 72.26 | 87.07 | 87.48 |
Total Liabilities | 35.17 | 35.9 | 36.37 | 28.37 |
Total Equity | 26.17 | 36.37 | 50.7 | 59.11 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -10.62 | -46.58 | -30.13 | -18.84 |
Cash From Investing Activities | -0.07 | 0.84 | -2.69 | -0.05 |
Cash From Financing Activities | 0.02 | 55.82 | 55.78 | 55.71 |
Net Change in Cash | -10.65 | 10.05 | 22.96 | 36.83 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review